Current Evidence Landscape
The research base for ACP therapy has expanded considerably over the past decade, with over 100 randomised controlled trials now published. Most studies focus on musculoskeletal conditions, particularly knee osteoarthritis, which accounts for approximately 40% of the research literature.
Systematic reviews and meta-analyses have begun appearing regularly since 2015, with the most comprehensive examining outcomes across different joint conditions. The Cochrane Collaboration has not yet produced a dedicated review, though individual Cochrane authors have contributed to systematic reviews in major journals.
Study quality varies significantly. While many recent trials meet methodological standards for randomisation and control groups, the inherent difficulty of blinding participants to injection treatments remains a persistent challenge across the field.
Strongest Research Findings
For knee osteoarthritis, a 2019 meta-analysis examining 24 trials with over 2,000 participants found statistically significant improvements in pain and function compared to placebo injections. Benefits typically emerged at 6-12 weeks and persisted for six months to one year. Effect sizes were moderate, with patients reporting 20-30% improvements on standardised pain scales.
Lateral epicondylitis (tennis elbow) shows similarly encouraging results. A systematic review of 11 trials involving nearly 500 patients demonstrated superior outcomes compared to corticosteroid injections at six months, with lower recurrence rates.
For rotator cuff tendinopathy, evidence is more mixed. While several trials show short-term benefits, improvements don't consistently exceed those seen with structured physiotherapy programmes.
Critical Limitations
The most significant limitation lies in protocol heterogeneity. Studies use different centrifugation speeds, platelet concentrations, injection volumes, and frequency schedules. This makes comparing results across trials problematic and limits our understanding of optimal treatment parameters.
Patient selection criteria also vary widely. Some studies include only mild arthritis, others encompass severe joint damage. Age ranges span from adolescent athletes to elderly patients, yet most analyses don't adequately account for these differences when reporting aggregate outcomes.
Blinding remains challenging. While placebo injections can control for injection effects, they cannot blind practitioners to the appearance of concentrated versus normal plasma. This may influence injection technique and post-treatment advice.
What We Can and Cannot Conclude
The evidence supports ACP therapy as a viable option for mild to moderate knee osteoarthritis and certain chronic tendinopathies, particularly when conventional treatments have proven insufficient. Benefits appear genuine rather than purely placebo-driven, based on trials with appropriate control groups.
However, we cannot determine which specific preparation method works best, how many injections provide optimal results, or which patients are most likely to respond. The therapy appears most effective in younger patients with less advanced joint damage, but clear selection criteria remain elusive.
Comparative effectiveness against established treatments like physiotherapy or viscosupplementation varies by condition and hasn't been definitively established.
Research Priorities
Future studies must standardise preparation protocols to enable meaningful comparison of results. Research networks are beginning to establish consensus guidelines for platelet concentration thresholds and centrifugation parameters.
Longer follow-up periods are essential. Most current trials track patients for 6-12 months, but understanding whether benefits persist beyond two years would inform treatment decision-making significantly.
Predictive biomarkers represent another crucial research direction. Identifying which patients are most likely to respond could improve outcomes and reduce unnecessary treatments. Early work suggests baseline inflammatory markers and imaging findings may prove useful, but validation in larger cohorts is needed.
